Tag: drug-coated devices

IN.PACT AV DCB sustained ‘superior’ effectiveness in subgroups with high reintervention...

Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of target...

Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy

Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results...

ACC.21: SAFE-PAD finds no increased risk of death with drug-coated devices

Researchers have found no statistically significant difference in mortality between patients treated with drug-coated devices and non-drug-coated devices in the SAFE-PAD study. Eric Secemsky,...

FDA representatives respond to SWEDEPAD interim analysis, highlight need for continued...

Representatives from the Food and Drug Administration (FDA) referenced "important and reassuring" results from the recent interim analysis of the SWEDEPAD clinical trial in which...